2,4,5,2',4',5'-hexabromobiphenyl

10/01/1986 - "Sequential study on the synergistic effects of 2,2',4,4',5,5'-hexabromobiphenyl and 3,3',4,4',5,5'-hexabromobiphenyl on hepatic tumor promotion."
09/29/2021 - "Some chemicals appeared in larger concentrations in diffuse-GC or other cancer groups, including some PCDDs, PCB105, 123, 138, PBDE209, and PBB153. "
11/01/1983 - "345-HBB, at a dietary concentration of 0.1 mg/kg, caused a physiologic response in rats as determined by induction of hepatic microsomal drug metabolizing enzymes, but there was minimal evidence of toxicity and no evidence of tumor-promoting ability. "
11/01/1983 - "Results indicate that there can be induction of MC type of hepatic microsomal drug-metabolizing enzymes without toxicity or tumor-promoting ability and that the tumor-promoting ability of 345-HBB was most likely the result of hepatic degeneration and necrosis. "
11/01/1983 - "Female Sprague-Dawley rats were fed diets containing 0, 0.01, 0.1, or 1.0 mg/kg 3,3',4,4',5,5'-hexabromobiphenyl (345-HBB) for 140 days after a 70% partial hepatectomy and diethylnitrosamine administration (10 mg/kg body weight) to determine if 345-HBB had tumor-promoting ability in a two-stage hepatocarcinogenesis assay. "

01/01/2023 - "Investigations into mechanisms to accelerate elimination and reduce body burdens of PBB-153, especially those related to body weight, are needed."
07/01/1994 - "The porphyrinogenic action of 2,2',4,4',5,5'-hexabromobiphenyl and its toxicokinetics were studied in female Wistar rats that were treated every other day for 6 wk with oral doses of 112 mg/kg body weight. "
11/01/1983 - "Female Sprague-Dawley rats were fed diets containing 0, 0.01, 0.1, or 1.0 mg/kg 3,3',4,4',5,5'-hexabromobiphenyl (345-HBB) for 140 days after a 70% partial hepatectomy and diethylnitrosamine administration (10 mg/kg body weight) to determine if 345-HBB had tumor-promoting ability in a two-stage hepatocarcinogenesis assay. "

01/01/2023 - "A significant interaction between being male and a high prevalence of COPD was observed for PBDE-28 (P for interaction <0.05), PBDE-47 (P for interaction <0.05), PBDE-85 (P for interaction <0.05), PBDE-99 (P for interaction <0.05), PBDE-100 (P for interaction <0.05), and PBB-153 (P for interaction < 0.05). "
01/01/2023 - "After adjustment for all confounding factors, log-transformed continuous serum PBDE-28 (OR: 1.43; 95% CI: 1.10-1.85; P = 0.01), PBDE-47 (OR: 1.39; 95% CI: 1.11-1.75; P = 0.005), PBDE-85 (OR: 1.31; 95% CI: 1.09-1.57; P = 0.005), PBDE-99 (OR: 1.27; 95% CI: 1.05-1.54; P = 0.02), PBDE-100 (OR: 1.33; 95% CI: 1.08-1.66; P = 0.01), PBDE-154 (OR: 1.29; 95% CI: 1.07-1.55; P = 0.01), PBDE-183 (OR: 1.31; 95% CI: 1.04-1.66; P = 0.02), and PBB-153 (OR: 1.25; 95% CI: 1.03-1.53; P = 0.03) were positively correlated with the prevalence of COPD. "

09/01/2008 - "PBB-153 was also positively associated with the prevalence of metabolic syndrome with adjusted odds ratios of 1.0, 1.5, 3.1, 3.1, and 3.1 (P for trend<0.01). "

01/01/1987 - "Firemaster BP-6 (FM), a mixture of polybrominated biphenyls (PBB), and the congeners 2,2',4,4',5,5'-hexabromobiphenyl (245-HBB), 3,3',4,4',5,5'-hexabromobiphenyl (345-HBB), and 3,3',4,4'-tetrabromobiphenyl (34-TBB) were tested for their ability to inhibit cell-cell communication between human teratocarcinoma cells in culture. "